In our current study, constitutive expression of either antisense or sense VEGF genes in the murine MOPC 315 plasmacytoma tumor cell line was utilized as a means to elucidate the effect of VEGF in the growth of plasmacytoma cells in vivo, as well as to directly address the possible application of antisense or sense VEGF gene therapy in the treatment of multiple myeloma. This evidence concerns the gene VEGFA and plasma cell myeloma.